2023 2022 2021 2020 2019 2018 2017 2016 2015

Pandiella, A, Calvo, E, Moreno, V, Amir, E, Templeton, A, Ocana, A. Considerations for the clinical development of immuno-oncology agents in cancer. FRONT IMMUNOL 14 -. 11 ago 2023. . . F.I.:5,700 [doi:10.3389/fimmu.2023.1229575]

Montero, JC, del Carmen, S, Abad, M, Sayagués, JM, Barbáchano, A, Fernández-Barral, A, Munoz, Alberto, Pandiella, A. An amino acid transporter subunit as an antibody-drug conjugate target in colorectal cancer. J EXP CLIN CANC RES 42 -. 9 ago 2023. . . F.I.:11,400 [doi:10.1186/s13046-023-02784-0]

Sanchez-Fdez, A, Matilla-Almazan, S, del Carmen, S, Abad, M, Arconada-Luque, E, Jimenez-Suarez, J, Chinchilla-Tabora, LM, Ruiz-Hidalgo, MJ, Sanchez-Prieto, R, Pandiella, A, Esparis-Ogando, A. Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications. EXP MOL MED 55 1247-1257. 1 jun 2023. 1 jun 2023. . F.I.:9,500 [doi:10.1038/s12276-023-01008-x]

Sanchez-Fdez, A, Matilla-Almazan, S, Montero, JC, Del Carmen, S, Abad, M, Garcia-Alonso, S, Bhattacharya, S, Calar, K, de la Puente, P, Ocana, A, Pandiella, A, Esparis-Ogando, A. The WNK1-ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib. CLIN TRANSL MED 13 -. 1 abr 2023. . . F.I.:7,900 [doi:10.1002/ctm2.1217]

Gandullo-Sanchez, L, Pandiella, A. An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs. CANCER LETT 554 -. 1 feb 2023. 1 dic 2022. . F.I.:9,100 [doi:10.1016/j.canlet.2022.216024]

Spinola-Lasso, E, Montero, JC, Jimenez-Monzon, R, Estevez, F, Quintana, J, Guerra, B, Elokely, KM, Leon, F, del Rosario, H, Fernandez-Perez, L, Lopez, MR, Diaz-Chico, BN, McNaughton-Smith, G, Pandiella, A, Diaz-Chico, JC. Chemical-proteomics Identify Peroxiredoxin-1 as an Actionable Target in Triple-negative Breast Cancer. INT J BIOL SCI 19 1731-1747. 1 ene 2023. . . F.I.:8,200 [doi:10.7150/ijbs.78554]